CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,735 enrolled
Drug / intervention
Allopurinoldrug
Likely dose
Allopurinol 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01391325
NCT01391325Phase 4Completed
CompareCT.gov

Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO)

Ardea Biosciences, Inc.·interventional·Posted Jul 12, 2011·Updated Jun 17, 2014

In Brief

A Phase 4 clinical trial evaluating Allopurinol for Gout. Completed, enrolled 1,735 participants across 173 sites in 7 countries.

Detailed Summary

This is a study of allopurinol in gout patients with hyperuricemia that will evaluate the safety and serum urate (sUA) lowering capability of allopurinol as a urate lowering therapy (ULT) for up to six months. Allopurinol will be dosed according to the local product label, at the discretion of the Investigator, to achieve an optimal, medically appropriate dose for each patient.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGout
CountriesAustralia, Belgium, Canada, Germany, New Zealand, South Africa, United States
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 12, 2011
Enrollment StartJul 1, 2011
Primary CompletionJan 1, 2013
Study CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.0 years ago

Interventions

Allopurinoldrug

Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.